February 2026 Research Update

This month added 2 practical signals about day-to-day FMF management in children: one focused on education and skills, and the other on whether colchicine is actually being taken as intended. Together, they highlight that measured adherence can be much lower than families expect, and that a digital training approach may improve confidence and reported compliance. These studies do not prove that education or adherence alone fully controls FMF, but they sharpen the picture of where gaps can happen and what might help close them. [1] [2]

In a pediatric study using the MASIF adherence tool, nearly three-quarters of children were rated as having poor colchicine adherence, and self-reported regular use often did not match what the tool found. Non-adherence also went along with more school absenteeism, suggesting that missed doses may be one piece of why daily life can be disrupted. Many common factors (such as age group or disease severity) were not clearly linked to adherence in this dataset, which makes the adherence problem look broad rather than limited to one subgroup. [1]

A small randomized trial tested a mobile game-based training program against a training booklet and no added training in children with FMF. The mobile game group showed improvements in self-efficacy, health-related quality of life, and therapeutic compliance, while the booklet had more limited effects and the control group stayed similar. The same trial also reported fewer symptoms and lower pain scores after the mobile game, alongside the improvements in coping and compliance. [2]

For families, the main message this month is that measuring adherence and supporting self-management may matter as much as simply asking whether colchicine is being taken. The education study is an early signal that some children may learn and cope better with interactive training than with written materials, but it is small and does not tell how well it would work in other settings. The adherence study suggests that missed doses may be common and can be overlooked, which could help explain ongoing disruptions like school absence, but it cannot prove that non-adherence caused those disruptions. [1] [2]

Across several studies, FMF severity and treatment needs looked different depending on age, genetics, and country background, but prediction tools did not perform equally well. Older adults in one center tended to have fewer attacks over time on colchicine, and people with different MEFV mutation locations had different symptom patterns while still often responding to colchicine. Attempts to predict colchicine resistance were mixed: one older scoring system did not generalize well, while newer AI-style models showed more promising accuracy in a large adult dataset. [3] [4] [5] [6] [7]

In a study of 343 FMF patients aged 50 or older, attack frequency and pain scores were lower after starting colchicine and remained low in the most recent year measured. In this dataset, being age 60 or older and being male were linked with fewer attacks, suggesting that disease activity may ease for some people later in life. Because this was based on routine records from one center, it describes patterns seen there rather than guaranteeing the same course for everyone. [3]

Genetics also lined up with different FMF experiences in an adult cohort comparing Exon 2 (such as E148Q and R202Q) with Exon 10 variants. Exon 2 was tied to later symptom onset and more muscle and joint symptoms, while Exon 10 was tied to more typical FMF features like fever and abdominal pain. Reported colchicine response was high in both groups, without a clear difference between them. [4]

A country comparison between Italian and Lebanese cohorts found broad differences in genetics, symptom burden, and the care pathway. Italians had older onset and longer diagnostic delay, fewer symptoms and attacks, and higher use of biologic drugs, while Lebanese patients more often carried pathogenic MEFV variants and had more severe disease. The same work also reported differences in misdiagnoses and disease knowledge, suggesting that both biology and health system factors may shape what living with FMF looks like in different places. [5]

Tools meant to predict colchicine resistance at diagnosis did not all hold up when tested outside the original setting. In a multinational registry, the TURPAID score had poor ability to separate colchicine-resistant from colchicine-sensitive patients, partly because heavy weighting for certain MEFV mutations led to many people being classified as higher risk. In contrast, a separate large adult dataset reported machine-learning and deep-learning models with an AUC of 0.79, and resistance differed by factors like homozygous mutations and arthritis features, though the summary did not describe how well these models perform in other populations. [6] [7]

For patients, this theme helps explain why FMF can feel very different from one person to another, even when the diagnosis name is the same. The age and genetics studies mainly add understanding of patterns (like later-onset, more joint symptoms in some genetic groups, and fewer attacks in some older adults), rather than changing what any one person should expect. For predicting colchicine resistance, this month clarified that at least one published score (TURPAID) may not work well across settings, while newer AI-based prediction is still early and needs confirmation in multiple real-world groups before it can be relied on. [3] [4] [5] [6] [7]

This month included several studies that look beyond classic fever attacks, asking how FMF shows up in the nervous system, the heart, and in testing during confusing symptoms. The pattern was that FMF can overlap with other conditions in symptoms (like abdominal pain or ankle pain), and some differences may be picked up with targeted tests or imaging. These studies are mainly about recognizing patterns, not about proving that any one test should be used routinely. [8] [9] [10] [11]

A small study comparing FMF patients with healthy controls found more symptoms suggesting autonomic nervous system changes (the system that helps control things like gut function, sweating, and bladder symptoms) in FMF. Objective testing showed lower resting parasympathetic function in FMF, while tests of sympathetic function were not clearly different between groups. Several autonomic measures also moved together with inflammation markers and with fatigue, sleep disturbance, anxiety or depression scores, and FMF-related quality of life scores. [8]

In a heart ultrasound study, mitral annular calcification (a calcium buildup near a heart valve) was less common in colchicine-treated FMF patients than in controls, even after considering factors like age and body weight. The authors suggested this could relate to long-term inflammation control or to colchicine itself, but the study design cannot confirm cause and effect. For patients, this mainly adds a research clue about how long-term inflammation and treatment might relate to certain heart findings. [9]

Two studies focused on distinguishing FMF from other diagnoses when symptoms overlap. In children with acute abdominal pain, a blood-count based inflammation marker (SII) and the neutrophil-to-lymphocyte ratio were higher in appendicitis than in FMF attacks, and a combined blood marker model separated the groups better than SII alone. In a small ankle muscle imaging comparison, FMF more often showed enthesitis-type features (inflammation where tendons attach to bone), while chronic nonbacterial osteomyelitis showed more bone-focused inflammation and juvenile arthritis showed more lining inflammation, though some comparisons were not clearly different. [10] [11]

For patients and caregivers, these studies help put words and possible explanations to symptoms that do not always look like a typical FMF attack, such as bowel, bladder, sweating, fatigue, or ankle pain patterns. The autonomic and heart findings are early and do not tell whether treating FMF differently would change these measures, but they support the idea that inflammation may affect multiple body systems. The diagnostic studies suggest that blood tests and ankle imaging patterns may sometimes help sort FMF from look-alike conditions, but they do not establish a single definitive test for real-world decision making. [8] [9] [10] [11]

One larger real-world pediatric study compared 2 anti-IL-1 medicines used when FMF does not respond well to colchicine. Both anakinra and canakinumab were linked with lower disease activity and lower inflammation markers over time, but their day-to-day tradeoffs differed. This adds practical detail about what families might experience with these medicines in routine care, while still leaving open questions about long-term outcomes. [12]

In 86 children with colchicine-resistant FMF, both anakinra and canakinumab were reported to reduce attack frequency, disease activity scores, and markers like CRP and serum amyloid A compared with baseline. Canakinumab had lower disease activity scores at 12 months and longer treatment retention, while anakinra was described as having faster symptom control but more injection-site reactions that often led to stopping it. Rare serious events were reported, including acute myeloid leukemia and inflammatory bowel disease, but the study could not establish whether these were caused by treatment. [12]

For families facing colchicine-resistant FMF, this study supports that anti-IL-1 medicines can be linked with meaningful drops in attacks and inflammation markers in real-world pediatric care. It also clarifies that the experience may differ between drugs, with injection-site reactions being a common reason for stopping anakinra, while canakinumab may be easier to stay on for some children in this dataset. Because the evidence is retrospective and not randomized, it cannot prove one medicine is better for all children, but it adds clearer expectations about patterns of response and tolerability that may matter now. [12]

This month included individual case reports showing that FMF can present in atypical ways and can overlap with other inflammatory conditions, plus a separate dataset highlighting the potential seriousness of pediatric colchicine poisoning. The shared message is that context matters: single cases can illustrate what is possible but not what is typical, while poison center data describes rare but important outcomes after exposures. Together, these reports expand awareness of unusual presentations and medication risks without redefining everyday expectations for most families. [13] [14] [15]

One case described a 16-year-old with recurrent abdominal pain after COVID-19 but without fever, later found to have a homozygous MEFV E148Q variant. Colchicine was reported to suppress attacks, and stool and blood inflammation markers normalized within 1 month. This case adds an example that FMF can sometimes look unusual and still respond to standard therapy, but it does not show how often this happens. [13]

Another case described a 40-year-old woman with psoriasis and FMF who developed temporomandibular joint fibrous ankylosis, leading to worsening mouth opening limits despite repeated procedures and conservative care. She ultimately required open joint surgery with arthroplasty. This report mainly highlights that complex joint problems can occur in people with inflammatory diseases, but it cannot tell whether FMF was the cause. [14]

A UK poisons database review of 57 pediatric colchicine exposures found that gastrointestinal symptoms were common, and a smaller group progressed to systemic toxicity. Outcome data were only available for 13 cases, but the report included severe outcomes in some children, including multiple organ failure and deaths, with fatalities occurring in mixed overdoses. This dataset underlines that colchicine exposures can be dangerous in children, even though it does not describe typical prescribed use in FMF care. [15]

For patients and caregivers, these reports mostly add awareness rather than changing routine understanding of FMF. The case reports help show that FMF can sometimes present without classic features like fever, and that symptoms can overlap with other inflammatory problems, but single cases cannot predict what will happen for others. The poison center study is more directly about safety, showing that pediatric colchicine exposure can lead to serious harm in some reported situations, although the available outcome information was limited and included mixed overdoses. [13] [14] [15]